Role of the renin-angiotensin system in vascular inflammation

被引:350
作者
Marchesi, Chiara
Paradis, Pierre
Schiffrin, Ernesto L. [1 ]
机构
[1] McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.tips.2008.05.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiotensin (Ang) II, the main effector of the renin-angiotensin system (RAS), is one of the major mediators of vascular remodeling in hypertension. Besides being a potent vasoactive peptide, Ang II exerts proinflammatory effects on the vasculature by inducing integrins, adhesion molecules, cytokines and growth and profibrotic mediators through activation of redox-sensitive pathways and transcription factors. Clinical findings suggest that inflammation participates in the mechanisms involved in the pathophysiology of hypertension and its complications. Antagonists of the RAS have been shown to exert cardiovascular protection, in part through their vascular anti-inflammatory effects. However, further studies are needed to better understand whether inflammatory biomarkers might be clinically useful for cardiovascular risk stratification and whether targeting inflammation pharmacologically will improve cardiovascular outcomes beyond blood pressure reduction. The present review addresses recent findings regarding the pathophysiology of vascular inflammation in hypertension, focusing specifically on the role of Ang II.
引用
收藏
页码:367 / 374
页数:8
相关论文
共 73 条
[1]   Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines [J].
Abu Nabah, YN ;
Mateo, T ;
Estellés, R ;
Mata, M ;
Zagorski, J ;
Sarau, H ;
Cortijo, J ;
Morcillo, EJ ;
Jose, PJ ;
Sanz, MJ .
CIRCULATION, 2004, 110 (23) :3581-3586
[2]   Direct evidence of leukocyte adhesion in arterioles by angiotensin II [J].
Alvarez, A ;
Cerda-Nicolás, M ;
Nabah, YNA ;
Mata, M ;
Issekutz, AC ;
Panés, J ;
Lobb, RR ;
Sanz, MJ .
BLOOD, 2004, 104 (02) :402-408
[3]   ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1 [J].
Amann, B ;
Tinzmann, R ;
Angelkort, B .
DIABETES CARE, 2003, 26 (08) :2421-2425
[4]   Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction [J].
Amiri, F ;
Virdis, A ;
Neves, MF ;
Iglarz, M ;
Seidah, NG ;
Touyz, RM ;
Reudelhuber, TL ;
Schiffrin, EL .
CIRCULATION, 2004, 110 (15) :2233-2240
[5]   Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis [J].
Aso, Yoshimasa .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :2957-2966
[6]   Blood pressure, C-reactive protein, and risk of future cardiovascular events [J].
Blake, GJ ;
Rifai, N ;
Buring, JE ;
Ridker, PM .
CIRCULATION, 2003, 108 (24) :2993-2999
[7]   Vascular inflammation and the renin-angiotensin system [J].
Brasier, AR ;
Recinos, A ;
Eledrisi, MS .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (08) :1257-1266
[8]   Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries [J].
Brassard, P ;
Amiri, F ;
Schiffrin, EL .
HYPERTENSION, 2005, 46 (03) :598-606
[9]   Prognostic value of myeloperoxidase in patients with chest pain [J].
Brennan, M ;
Penn, MS ;
Van Lente, F ;
Nambi, V ;
Shishehbor, MH ;
Aviles, RJ ;
Goormastic, M ;
Pepoy, ML ;
McErlean, ES ;
Topol, EJ ;
Nissen, SE ;
Hazen, SL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (17) :1595-1604
[10]   Aldosterone and vascular inflammation [J].
Brown, Nancy J. .
HYPERTENSION, 2008, 51 (02) :161-167